• Explore /
  • Poster
  • / Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III ΜΡΑCT study of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).

Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III ΜΡΑCT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).

Abstract Poster

Authors

null

David Goldstein

Prince of Wales Hospital, Sydney, Australia

David Goldstein , Robert Hassan El-Maraghi , Pascal Hammel , Volker Heinemann , Volker Kunzmann , Javier Sastre , Werner Scheithauer , Salvatore Siena , Teresa Macarulla , Luis Teixeira , Giampaolo Tortora , Jean Luc Van Laethem , Darryl Neil Penenberg , Brian Lu , Alfredo Romano , Daniel D. Von Hoff

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT00844649

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 4027^)

DOI

10.1200/jco.2014.32.15_suppl.4027

Abstract #

4027^

Poster Bd #

46

Abstract Disclosures

Similar Posters

First Author: David Goldstein

First Author: E. Gabriela Chiorean

First Author: Guifang Guo

First Author: Benedikt Westphalen